Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
Zur Ablage hinzufügen
  Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben
Zeitschriftenartikel

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma

MPG-Autoren
/persons/resource/persons278011

Jachimowicz,  R. D.
Jachimowicz – Mechanisms of DNA Repair, Max Planck Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society;

Externe Ressourcen

https://www.ncbi.nlm.nih.gov/pubmed/23225085
(beliebiger Volltext)

Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte in PuRe verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Sauer, M., Plutschow, A., Jachimowicz, R. D., Kleefisch, D., Reiners, K. S., Ponader, S., et al. (2012). Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol, 88(2), 113-5. doi:10.1002/ajh.23361.


Zitierlink: https://hdl.handle.net/21.11116/0000-000B-7234-A
Zusammenfassung
Hodgkin lymphoma (HL) has become one of the best curable cancers. However, better biomarkers are needed for outcome prediction that would allow protecting patients from over- or under-dosing of treatment. Thymus and activation-regulated chemokine/CCL17 (TARC) is highly and specifically elevated in this disease and has been proposed as possible biomarker in HL patients. In this study, we show that pretreatment TARC levels were associated with established clinical risk factors and predictive for response to treatment in a large cohort of HL patients treated in clinical trials by the German Hodgkin Study Group. Moreover, TARC levels also significantly contributed to a novel multivariate model predicting treatment response. These data clearly suggest an important role for this chemokine as biomarker in HL.